How close is CAR-T therapies for solid tumors to routine medical use?

Why CAR-T works for blood cancers but not yet for solid tumors

CAR-T cell therapy has been a breakthrough for certain blood cancers. Six CAR-T products are now FDA-approved for six different hematologic malignancies, including B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma [1]. In one trial, CAR-T therapy improved 4-year overall survival in large B-cell lymphoma from 46% to 54.6% compared to standard chemotherapy [1]. For multiple myeloma, CAR-T extended progression-free survival to 13.3 months versus 4.4 months with standard therapy [1]. These results are dramatic and have transformed treatment for thousands of patients.

Solid tumors are a fundamentally different challenge. The same therapy that achieves 80-97% complete remission rates in some blood cancers [2] has not replicated that success in solid tumors. A meta-analysis of 22 studies with 262 patients found the overall pooled response rate for CAR-T in solid tumors was just 9% (95% CI: 4-16%) [3]. This stark difference is not due to lack of effort—82% of the roughly 1,000 CAR-T clinical trials registered focus on blood cancers, while only 16% target solid tumors [2]—but because solid tumors present unique biological barriers that blood cancers do not.

The three main obstacles: getting in, staying alive, and hitting the right target

First, CAR-T cells struggle to physically infiltrate solid tumors. Unlike blood cancers where the malignant cells circulate in the bloodstream, solid tumors are dense masses surrounded by a physical barrier of connective tissue and abnormal blood vessels [4][6]. Even if CAR-T cells reach the tumor site, they must navigate a hostile microenvironment filled with immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) that actively shut down T-cell activity [9]. One study notes that MDSCs are a 'major obstacle' because they create an environment that suppresses CAR-T function [9].

Second, solid tumors are heterogeneous—they don't all express the same target antigen. CAR-T cells are engineered to recognize a specific protein on the surface of cancer cells. If some tumor cells lack that protein (antigen escape) or if the protein is also present on healthy tissues (on-target, off-tumor toxicity), the therapy either fails or causes dangerous side effects [6][8]. This is a fundamental problem: blood cancers tend to express uniform targets like CD19, but solid tumors often have patchy or variable antigen expression [5][14].

Third, the tumor microenvironment is immunosuppressive. Solid tumors actively secrete factors that exhaust CAR-T cells, causing them to lose their killing ability over time [5][7]. Researchers are exploring combinations with immune checkpoint inhibitors, targeted drugs, and even metformin (a diabetes drug) to boost CAR-T persistence and activity [7][11]. One innovative approach uses a hydrogel scaffold implanted after surgery to slowly release both CAR-T cells and metformin, which was shown to enhance CAR-T proliferation and tumor infiltration in mouse models [11].

Promising early results, but still experimental

Despite the challenges, there are glimmers of progress. The meta-analysis found that CAR-T therapy performed best in neuroblastoma, a childhood solid tumor, while it 'barely works' in gastrointestinal malignancies [3]. In pediatric solid tumors, early clinical trials targeting GD2 and HER2 antigens have shown encouraging but preliminary results that need validation in larger studies [14]. A 2023 review of CAR-T in children with solid tumors notes that while the concept is promising, effectiveness 'is still being investigated and remains an area of active research' [12].

Novel strategies are being tested to overcome the limitations. One team engineered probiotics that colonize tumors and release synthetic targets, essentially 'labeling' the tumor for CAR-T cells to attack—a system called ProCARs that showed safety and efficacy in multiple mouse cancer models [13]. Another approach uses nanomaterials to improve CAR-T cell manufacturing, reduce costs, and enhance delivery to tumors [10]. These are all preclinical or very early-stage clinical concepts; none have reached routine clinical use.

The bottom line: CAR-T for solid tumors is not close to routine medical use. The evidence consistently shows that while the field is actively researching solutions, the fundamental biological barriers have not yet been overcome. Patients should view CAR-T for solid tumors as an experimental therapy available only in clinical trials, with no guarantee of benefit. The most optimistic assessment from the studies here is that researchers remain 'optimistic about the future' [5] but acknowledge that 'most research is in development' [14].

About These Sources

This answer is built on 14 peer-reviewed studies — published from 2019 to 2025, 9 from 2024 or later, 12 in Q1 journals, collectively cited 844 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 72 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions